Jane Street Group, LLC Checkpoint Therapeutics, Inc. Transaction History

Jane Street Group, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.02 - $10.6 $31,134 - $323,554	30,524 Added 98.15%	61,623 $64,000
Q2 2022 Aug 16, 2022	BUY	$0.97 - $1.77 $30,166 - $55,045	31,099 New	31,099 $32,000
Q4 2021 Feb 15, 2022	SELL	$2.68 - $4.46 $32,677 - $54,380	-12,193 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$2.5 - $3.53 $36,290 - $51,241	-14,516 Reduced 54.35%	12,193 $40,000
Q2 2021 Aug 16, 2021	BUY	$2.36 - $3.2 $63,033 - $85,468	26,709 New	26,709 $79,000
Q1 2021 May 18, 2021	SELL	$2.6 - $4.16 $35,833 - $57,333	-13,782 Closed	0 $0
Q4 2020 Feb 17, 2021	BUY	$2.19 - $2.96 $30,182 - $40,794	13,782 New	13,782 $37,000
Q3 2019 Nov 14, 2019	SELL	$2.15 - $3.36 $67,763 - $105,900	-31,518 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$2.75 - $5.0 $86,674 - $157,590	31,518 New	31,518 $95,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $234M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.